Humana Faces Setback in Legal Battle
Humana Co., Ltd. (NYSE:HUM) recently lost a legal case aimed at lowering its insurance premiums. With Medicare Advantage Bonus payments on the horizon, concerns are growing about potential revenue losses that could reach billions.
On Tuesday, reports indicated that a Texas judge ruled in favor of the federal government, maintaining the decision to downgrade Humana’s star rating. This star rating is crucial because it directly affects the payments private insurers receive through Medicare Advantage.
This ruling is a notable setback for Humana, which contended that the government’s decision to lower its ratings was based on just three unsuccessful phone calls—a move the company described as “arbitrary and capricious.”
In the ruling, the judge upheld the government’s evaluation of the calls, dismissing Humana’s claims. Interestingly, other companies like United Health Group Co., Ltd. (NYSE:UNH), Elevance Health Co., Ltd. (NYSE:ELV), and SCAN Health Plan have successfully defended similar cases in recent years.
Humana’s dependency on Medicare Advantage makes this ruling particularly troubling. An August estimate from Capstone valued Humana’s payouts at around $3 billion. A strong star rating, which evaluates the performance of Medicare Advantage plans, directly impacts bonus payments from the federal government.
According to Bloomberg, data from the Kaiser Family Foundation indicates that total bonus payments to insurance companies could exceed $12.7 billion by 2025. This suggests that a drop in Humana’s ratings might have severe financial repercussions.
The legal loss represents a significant threat to Humana’s financial health. The company has historically depended more on Medicare Advantage revenue compared to its larger competitors.
In July, Humana reported an adjusted earnings per share (EPS) of $6.27 for the second quarter, down from $6.96 the previous year, though it did surpass estimates of $5.90. Sales were up at $32.39 billion, compared to a consensus of $31.89 billion.
Looking ahead, Humana anticipates adjusted earnings of approximately $17 per share in 2025, marking an increase from earlier guidance of $16.25 and consensus expectations of $16.36. This latest forecast includes about $100 million in investments aimed at enhancing member and patient outcomes while supporting operational excellence.
In reaction to the announcement, Humana’s stock dropped 3.24% to $262.22, according to data from the company.
